Carter Gould
Stock Analyst at Cantor Fitzgerald
(4.07)
# 1,638
Out of 4,504 analysts
635
Total ratings
51.4%
Success rate
6%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintained: Buy | $1,230 → $1,350 | $1,188.58 | +13.58% | 100 | Jul 6, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintained: Buy | $800 → $750 | $664.52 | +12.86% | 52 | Jul 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $590 | $485.39 | +21.55% | 10 | Jul 6, 2026 | |
| ABBV AbbVie | Maintained: Buy | $240 → $265 | $248.08 | +6.82% | 49 | Jul 6, 2026 | |
| PFE Pfizer | Maintained: Hold | $27 | $24.17 | +11.71% | 60 | Jun 22, 2026 | |
| GILD Gilead Sciences | Maintained: Buy | $155 | $129.83 | +19.39% | 48 | Jun 21, 2026 | |
| AMGN Amgen | Maintained: Hold | $350 | $363.39 | -3.68% | 48 | Apr 30, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $45 → $54 | $57.58 | -6.22% | 35 | Apr 8, 2026 | |
| MRK Merck & Co. | Maintained: Hold | $120 | $123.54 | -2.87% | 44 | Mar 29, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | n/a | $84.87 | - | 18 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $58.21 | n/a | 2 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $199.15 | n/a | 45 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $56.59 | n/a | 24 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.1697 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.14 | n/a | 14 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $1.50 | n/a | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.61 | n/a | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $177.11 | n/a | 29 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.6378 | n/a | 9 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $160 | $222.28 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $37 | $115.61 | n/a | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | €81.24 | $139.70 | n/a | 1 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $82 → $86 | $116.71 | n/a | 4 | Jul 31, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $94 | $547.06 | n/a | 1 | May 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $4 | $2.39 | n/a | 2 | Feb 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 → $2.8 | $9.46 | n/a | 2 | Jan 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $13 | $0.8175 | n/a | 2 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $75 | $3.18 | n/a | 3 | May 16, 2018 |
Eli Lilly and Company
Jul 6, 2026
Maintained: Buy
Price Target: $1,230 → $1,350
Current: $1,188.58
Upside: +13.58%
Regeneron Pharmaceuticals
Jul 6, 2026
Maintained: Buy
Price Target: $800 → $750
Current: $664.52
Upside: +12.86%
Vertex Pharmaceuticals
Jul 6, 2026
Maintained: Buy
Price Target: $590
Current: $485.39
Upside: +21.55%
AbbVie
Jul 6, 2026
Maintained: Buy
Price Target: $240 → $265
Current: $248.08
Upside: +6.82%
Pfizer
Jun 22, 2026
Maintained: Hold
Price Target: $27
Current: $24.17
Upside: +11.71%
Gilead Sciences
Jun 21, 2026
Maintained: Buy
Price Target: $155
Current: $129.83
Upside: +19.39%
Amgen
Apr 30, 2026
Maintained: Hold
Price Target: $350
Current: $363.39
Upside: -3.68%
Bristol-Myers Squibb Company
Apr 8, 2026
Maintained: Hold
Price Target: $45 → $54
Current: $57.58
Upside: -6.22%
Merck & Co.
Mar 29, 2026
Maintained: Hold
Price Target: $120
Current: $123.54
Upside: -2.87%
Cytokinetics
Feb 25, 2026
Maintained: Buy
Price Target: n/a
Current: $84.87
Upside: -
Jun 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $58.21
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $199.15
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $56.59
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $0.1697
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $19.14
Upside: n/a
Nov 8, 2024
Rated: Buy
Price Target: $9
Current: $1.50
Upside: n/a
Nov 7, 2024
Maintained: Buy
Price Target: $12
Current: $1.61
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $160
Current: $177.11
Upside: n/a
Aug 14, 2024
Maintained: Buy
Price Target: $3
Current: $0.6378
Upside: n/a
Jan 11, 2023
Rated: Hold
Price Target: $160
Current: $222.28
Upside: n/a
Dec 7, 2022
Initiated Coverage: Buy
Price Target: $37
Current: $115.61
Upside: n/a
Feb 27, 2020
Initiated Coverage: Buy
Price Target: €81.24
Current: $139.70
Upside: n/a
Jul 31, 2019
Maintained: Hold
Price Target: $82 → $86
Current: $116.71
Upside: n/a
May 17, 2019
Upgraded: Hold
Price Target: $94
Current: $547.06
Upside: n/a
Feb 1, 2019
Downgraded: Hold
Price Target: $16 → $4
Current: $2.39
Upside: n/a
Jan 11, 2019
Maintained: Hold
Price Target: $6 → $2.8
Current: $9.46
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: $18 → $13
Current: $0.8175
Upside: n/a
May 16, 2018
Maintained: Buy
Price Target: $90 → $75
Current: $3.18
Upside: n/a